These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 39359691)

  • 1. Radiofrequency ablation: mechanisms and clinical applications.
    Wu J; Zhou Z; Huang Y; Deng X; Zheng S; He S; Huang G; Hu B; Shi M; Liao W; Huang N
    MedComm (2020); 2024 Oct; 5(10):e746. PubMed ID: 39359691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incomplete radiofrequency ablation induced chemoresistance by up-regulating heat shock protein 70 in hepatocellular carcinoma.
    Wang F; Xu C; Li G; Lv P; Gu J
    Exp Cell Res; 2021 Dec; 409(2):112910. PubMed ID: 34801560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ruthenium Complex Suppresses Proliferation of Residual Hepatocellular Carcinoma after Incomplete Radiofrequency Ablation Therapy.
    Yu ZJ; Guo SW; Wang BS; Ouyang S; Zhang XH; Zhao ZZ; Wang JQ
    Recent Pat Anticancer Drug Discov; 2024 Aug; ():. PubMed ID: 39136523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Overview of Hepatocellular Carcinoma After Insufficient Radiofrequency Ablation.
    Guo Y; Ren Y; Dong X; Kan X; Zheng C
    J Hepatocell Carcinoma; 2022; 9():343-355. PubMed ID: 35502292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous inhibition of heat shock proteins and autophagy enhances radiofrequency ablation of hepatocellular carcinoma.
    Zhao J; Lei L; Dai W; Jiang A; Jin Q; Tang Z
    Biomater Sci; 2024 Nov; 12(23):6082-6098. PubMed ID: 39429155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated proteogenomic characterization reveals an imbalanced hepatocellular carcinoma microenvironment after incomplete radiofrequency ablation.
    Shi ZR; Duan YX; Cui F; Wu ZJ; Li MP; Song PP; Peng QL; Ye WT; Yin KL; Kang MQ; Yu YX; Yang J; Tang W; Liao R
    J Exp Clin Cancer Res; 2023 May; 42(1):133. PubMed ID: 37231509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic effect of OK-432 in combination with an anti-PD-1 antibody for residual tumors after radiofrequency ablation of hepatocellular carcinoma.
    Sun T; Sun B; Cao Y; Liu J; Chen J; Liang B; Zheng C; Kan X
    Biomed Pharmacother; 2023 Oct; 166():115351. PubMed ID: 37625323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. All-trans retinoic acid (ATRA) inhibits insufficient radiofrequency ablation (IRFA)-induced enrichment of tumor-initiating cells in hepatocellular carcinoma.
    Wang S; Liu J; Wu H; Jiang A; Zhao K; Yan K; Wu W; Han H; Zhang Y; Yang W
    Chin J Cancer Res; 2021 Dec; 33(6):694-707. PubMed ID: 35125813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insufficient radiofrequency ablation promotes hepatocellular carcinoma cell progression via autophagy and the CD133 feedback loop.
    Wang X; Deng Q; Feng K; Chen S; Jiang J; Xia F; Ma K; Bie P
    Oncol Rep; 2018 Jul; 40(1):241-251. PubMed ID: 29749472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melatonin enhances the efficacy of anti-PD-L1 by improving hypoxia in residual tumors after insufficient radiofrequency ablation.
    Ren Y; Zhu L; Guo Y; Ma J; Yang L; Zheng C; Dong X
    J Pharm Anal; 2024 Aug; 14(8):100942. PubMed ID: 39263355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insufficient radiofrequency ablation promotes proliferation of residual hepatocellular carcinoma via autophagy.
    Zhao Z; Wu J; Liu X; Liang M; Zhou X; Ouyang S; Yao J; Wang J; Luo B
    Cancer Lett; 2018 May; 421():73-81. PubMed ID: 29458142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endovascular radiofrequency ablation for varicose veins: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2011; 11(1):1-93. PubMed ID: 23074413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STING agonist-based hydrogel enhances immune activation in synergy with radiofrequency ablation for hepatocellular carcinoma treatment.
    Ao F; Li X; Tan Y; Jiang Z; Yang F; Guo J; Zhu Q; Chen Z; Zhou B; Zhang K; Li D
    J Control Release; 2024 May; 369():296-308. PubMed ID: 38301925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insufficient radiofrequency ablation-induced autophagy contributes to the rapid progression of residual hepatocellular carcinoma through the HIF-1α/BNIP3 signaling pathway.
    Xu WL; Wang SH; Sun WB; Gao J; Ding XM; Kong J; Xu L; Ke S
    BMB Rep; 2019 Apr; 52(4):277-282. PubMed ID: 30940322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harnessing endoscopic ultrasound-guided radiofrequency ablation to reshape the pancreatic ductal adenocarcinoma microenvironment and elicit systemic immunomodulation.
    Moond V; Maniyar B; Harne PS; Bailey-Lundberg JM; Thosani NC
    Explor Target Antitumor Ther; 2024; 5(5):1056-1073. PubMed ID: 39351436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Periprocedural risk factors for incomplete radiofrequency ablation of liver metastases from colorectal cancer: a single-center retrospective analysis.
    Fan H; Wang X; Qu J; Lu W; Pang Z; Shao T; Xia J; Wang H; Li G; Zhang Y; Sun J; Yang X
    Int J Hyperthermia; 2021; 38(1):985-994. PubMed ID: 34167430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A well-matched marriage of immunotherapy and radiofrequency ablation to reduce the relapse and progression of hepatocellular carcinoma.
    Liao R; Song P; Duan Y; Ye W; Yin K; Kang M; Yu Y; Yang J; Tang W
    Biosci Trends; 2022 Nov; 16(5):377-380. PubMed ID: 36089338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical short-term results of radiofrequency ablation in primary and secondary liver tumors.
    Jiao LR; Hansen PD; Havlik R; Mitry RR; Pignatelli M; Habib N
    Am J Surg; 1999 Apr; 177(4):303-6. PubMed ID: 10326848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eliminating METTL1-mediated accumulation of PMN-MDSCs prevents hepatocellular carcinoma recurrence after radiofrequency ablation.
    Zeng X; Liao G; Li S; Liu H; Zhao X; Li S; Lei K; Zhu S; Chen Z; Zhao Y; Ren X; Su T; Cheng AS; Peng S; Lin S; Wang J; Chen S; Kuang M
    Hepatology; 2023 Apr; 77(4):1122-1138. PubMed ID: 35598182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HSP90 inhibitor, XL888, enhanced cell apoptosis via downregulating STAT3 after insufficient radiofrequency ablation in hepatocellular carcinoma.
    Sun C; Bai M; Ke W; Wang X; Zhao X; Lu Z
    Life Sci; 2021 Oct; 282():119762. PubMed ID: 34186047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.